186 related articles for article (PubMed ID: 14688462)
1. Recent advances of molecular targeted agents: opportunities for imaging.
Dancey JE
Cancer Biol Ther; 2003; 2(6):601-9. PubMed ID: 14688462
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).
Hochhaus A
Ann Hematol; 2004; 83 Suppl 1():S65-6. PubMed ID: 15124676
[No Abstract] [Full Text] [Related]
3. The era of personalized medicine: back to basics.
Hutchinson L; DeVita VT
Nat Clin Pract Oncol; 2008 Nov; 5(11):623. PubMed ID: 18957968
[No Abstract] [Full Text] [Related]
4. [Molecular diagnosis of solid tumors].
Yatabe Y
Nihon Rinsho; 2005 Mar; 63(3):434-40. PubMed ID: 15773342
[TBL] [Abstract][Full Text] [Related]
5. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
Petrelli A; Giordano S
Curr Med Chem; 2008; 15(5):422-32. PubMed ID: 18288997
[TBL] [Abstract][Full Text] [Related]
6. [The mechanisms of the resistance to molecular targeting agents].
Akiyama S
Nihon Rinsho; 2004 Jul; 62(7):1297-304. PubMed ID: 15283147
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapies for cancer 2004.
Ross JS; Schenkein DP; Pietrusko R; Rolfe M; Linette GP; Stec J; Stagliano NE; Ginsburg GS; Symmans WF; Pusztai L; Hortobagyi GN
Am J Clin Pathol; 2004 Oct; 122(4):598-609. PubMed ID: 15487459
[TBL] [Abstract][Full Text] [Related]
8. [Targeted treatment of cancers with imatinib mesylate (STI571, Gleevec): results of Asco 2002].
Ray-Coquard I; Blay JY
Bull Cancer; 2002 Jun; 89(6):567-9. PubMed ID: 12135855
[No Abstract] [Full Text] [Related]
9. Outpacing cancer.
Dorans K
Nat Med; 2009 Jul; 15(7):718-22. PubMed ID: 19584848
[No Abstract] [Full Text] [Related]
10. [Antineoplastic agents targeting tyrosine kinases].
Guren TK; Christoffersen T; Thoresen GH; Wisløff F; Dajani O; Tveit KM
Tidsskr Nor Laegeforen; 2005 Nov; 125(22):3115-9. PubMed ID: 16299568
[TBL] [Abstract][Full Text] [Related]
11. [Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor].
Nakajima M; Toga W
Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):482-90. PubMed ID: 14639002
[TBL] [Abstract][Full Text] [Related]
12. Cancer treatment. New drugs, new hope.
Harv Health Lett; 2001 Jul; 26(9):1-3. PubMed ID: 11511447
[No Abstract] [Full Text] [Related]
13. Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy.
Becker JC; Muller-Tidow C; Serve H; Domschke W; Pohle T
World J Gastroenterol; 2006 Jun; 12(21):3297-305. PubMed ID: 16733844
[TBL] [Abstract][Full Text] [Related]
14. Imatinib: paradigm or anomaly?
Druker BJ
Cell Cycle; 2004 Jul; 3(7):833-5. PubMed ID: 15254412
[TBL] [Abstract][Full Text] [Related]
15. Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents.
Kim R; Toge T
Surg Today; 2004; 34(4):293-303. PubMed ID: 15052442
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).
Metro G; Finocchiaro G; Toschi L; Bartolini S; Magrini E; Cancellieri A; Trisolini R; Castaldini L; Tallini G; Crino L; Cappuzzo F
Rev Recent Clin Trials; 2006 Jan; 1(1):1-13. PubMed ID: 18393776
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology of imatinib (STI571).
Buchdunger E; O'Reilly T; Wood J
Eur J Cancer; 2002 Sep; 38 Suppl 5():S28-36. PubMed ID: 12528770
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting tyrosine kinases: successes and limitations.
Arteaga CL
Cancer Biol Ther; 2003; 2(4 Suppl 1):S79-83. PubMed ID: 14508084
[TBL] [Abstract][Full Text] [Related]
20. Innovations in antineoplastic therapy.
Kaplow R
Nurs Clin North Am; 2005 Mar; 40(1):77-94. PubMed ID: 15733948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
